Nature Communications, 2023 Chimeric antigen receptors (CARs) and synthetic Notch (synNotch) receptors are engineered cell-surface receptors that sense a target antigen and respond by activating T cell receptor signaling or a customized gene program, respectively.
Elisa Ruffo +10 more
doaj +1 more source
Clinical implications of antigen transfer mechanisms from malignant to dendritic cells: Exploiting cross-priming [PDF]
, 2002 Expansion and activation of cytolytic T lymphocytes bearing high-affinity T-cell receptors specific for tumor antigens is a major goal of active cancer immunotherapy.
Alfaro, C. (Carlos) +9 more
core +1 more source
Comparison of lentiviral and sleeping beauty mediated αβ T cell receptor gene transfer.
PLoS ONE, 2013 Transfer of tumour antigen-specific receptors to T cells requires efficient delivery and integration of transgenes, and currently most clinical studies are using gamma retroviral or lentiviral systems.
Anne-Christine Field +9 more
doaj +1 more source
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Acta Pharmaceutica Sinica B, 2018 Chimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR).
Zijun Zhao +4 more
doaj +1 more source
Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy [PDF]
, 2016 Due to the lack of specificity for tumor antigens, allogeneic T-cell therapy is associated with graft-versus-host disease. Enhancing the anti-tumor specificity while reducing the graft-versus-host disease risk of allogeneic T cells has remained a ...
Chakraverty, R +9 more
core +3 more sources
T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies
Nature Communications, 2022 AbstractThe success of chimeric antigen receptor (CAR) T cells in treating B cell malignancies comes at the price of eradicating normal B cells. Even though T cell malignancies are aggressive and treatment options are limited, similar strategies for T cell malignancies are constrained by the severe immune suppression arising from bystander T cell ...
Fanlin Li +17 more
openaire +3 more sources
Genome-Edited T Cell Therapies [PDF]
, 2017 PURPOSE OF REVIEW: Alternative approaches to conventional drug-based cancer treatments have seen T cell therapies deployed more widely over the last decade.
Delhove, JMKM, Qasim, W
core +1 more source
Intravitreal GD2‐Specific Chimeric Antigen Receptor T‐Cell Therapy for Refractory Retinoblastoma
Pediatric Blood &Cancer, EarlyView.ABSTRACT Effective treatments for advanced, treatment‐resistant retinoblastoma (RB) remain limited. GD2‐specific chimeric antigen receptor (CAR) T cells show potent antitumor activity with minimal toxicity but have not previously been evaluated in RB.
Subongkoch Subhadhirasakul +13 more
wiley +1 more source
Expression of interleukin 2 receptors on activated human B cells. [PDF]
, 1984 Using anti-Tac, a monoclonal anti-interleukin 2 (IL-2) receptor antibody, we have explored the possibility that certain activated B cells display receptors for IL-2.
Bongiovanni, KF +8 more
core
An Influenza Virus M2 Protein Specific Chimeric Antigen Receptor Modulates Influenza A/WSN/33 H1N1 Infection In Vivo [PDF]
, 2013 A potential target for the development of universal vaccine strategies against Influenza A is the M2 protein – a membrane protein with a highly conserved extracellular domain.
Blair, Natalie F +5 more
core +1 more source